Fampridine treatment and walking distance in multiple sclerosis:A randomised controlled trial

Modified-release fampridine is a slow release form of 4-aminopyridine that has been approved worldwide for the treatment of multiple sclerosis-related walking disability. Recent phase II and phase III studies of fampridine have demonstrated sustained clinical benefits on walking speed over short distances of 25 feet in ∼40% of MS patients (Goodman et al., 2008; Goodman et al., 2009; Goodman et al., 2010). Unlike the short-release form of 4-aminopyridine which has significant adverse effects, including the development of seizures, fampridine has a more acceptable safety profile with a lower risk of serious adverse events in controlled trials (Goodman et al., 2009).

from Physiology via xlomafota13 on Inoreader http://ift.tt/2epACSF
via IFTTT